Genmab/Janssen Biotech's Daratumumab market size expected to increase many folds by 2032, report DelveInsight

DelveInsight has recently published a report on "Daratumumab Market Forecast Report" providing an in-depth analysis of the Daratumumab market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Daratumumab market potential and market share analysis in the AL Amyloidosis therapeutics space across the 7MM from 2019 to 2032.

The report also helps you to understand the Daratumumab clinical and commercial developments along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.

Interested in finding out the projected market size of Daratumumab by 2032? Visit: https://www.delveinsight.com/report-store/daratumumab-emerging-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Daratumumab Drug Summary

Daratumumab (marketed as DARZALEX) is an IgG1k monoclonal antibody and targeted therapy directed at CD38. It binds to a distinct CD38 epitope amino acid sequence, differing from those involved in inducing cell apoptosis through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis. These effects rely on immune effector mechanisms in the fragment crystallizable region. Natural killer cells are utilized in antibody-dependent cellular cytotoxicity.

DARZALEX FASPRO represents a subcutaneous formulation of daratumumab co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), utilizing ENHANZE drug delivery technology to enhance skin penetration.

Initially developed by Genmab, daratumumab is now a collaborative effort with Janssen Biotech, a subsidiary of Johnson & Johnson, which acquired global commercialization rights from Genmab. The drug has received orphan drug status for multiple myeloma, AL amyloidosis, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. The US FDA granted accelerated approval for Daratumumab based on the Phase III ANDROMEDA trial's results and response, establishing it as a first-line treatment for AL amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone (CyBorD) in 2021. Continued approval for this indication may be contingent upon verification and demonstration of clinical benefit in a confirmatory trial.
Stay ahead of the competition by leveraging key insights and evolving trends in the Daratumumab Market @ https://www.delveinsight.com/sample-request/daratumumab-emerging-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Highlights of the Daratumumab Market Report

The report contains forecasted sales evaluation of Daratumumab for AL Amyloidosis till 2032.
It provides comprehensive coverage of late-stage emerging therapies for AL Amyloidosis treatment.
The report also features qualitative and quantitative analysis with analysts, as well as KOL views for Daratumumab in AL Amyloidosis.

Why Daratumumab Market Report?
Leading Daratumumab for AL Amyloidosis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Daratumumab.
A thorough Daratumumab market forecast will help understand how the drug is competing with other emerging therapies in the therapeutics landscape.
It will help to get an analysis of the Daratumumab clinical trial advancements and the detailed clinical assessment, regulatory, and commercial assessment
The report also provides future market assessments for Daratumumab market for AL Amyloidosis in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in AL Amyloidosis.

Request the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/daratumumab-emerging-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports By DelveInsight:

AL Amyloidosis Market Outlook and Forecast
"AL Amyloidosis Market Insights, Epidemiology and Market Forecast 2032" report delivers an in-depth understanding of AL Amyloidosis, historical and forecasted epidemiology as well as the AL Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the AL Amyloidosis therapeutics landscape.

Top Services Offered By DelveInsight:
Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment

Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard

Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential

428, Corporate Park, Sector-21, Dwarka,
New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.